| Previous Close | 82.58 |
| Open | 82.42 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 82.30 - 83.26 |
| 52 Week Range | 66.72 - 92.97 |
| Volume | 2,028,464 |
| Avg. Volume | 2,365,474 |
| Market Cap | 101.09B |
| Beta | 0.74 |
| PE Ratio (TTM) | 11.45 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.49%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
Associated Press•10 hours agoEpiPen maker finalizes settlement for government overcharges
TRENTON, N.J. (AP) — EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade — charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government.
- American City Business Journals•13 hours ago
EpiPen maker settles federal claims for $465M a year after Sanofi filed suit
Mylan NV will pay $465 million fine to settle claims brought by the U.S. Justice Department that it overcharged the government for its emergency allergy drug, EpiPen. French drug company Sanofi, the parent company of the state’s largest biotech employer, Sanofi Genzyme (SNY), first brought the matter to the attention of the U.S. Attorney’s Office in 2014 because it was selling a competing epinephrine auto-injector drug called AUVI-Q. In 2016, Sanofi filed a complaint in Massachusetts federal court against Mylan under the False Claims Act, which permits private parties to sue on behalf of the government and to receive a share of any recovery.
- TheStreet.com•13 hours ago
Mylan Finalizes $465 Million EpiPen Settlement With DoJ
The dispute became the center of a drug price firestorm.
